Phase II study of vinorelbine (NVB) and UFT in patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes.

被引：0
|
作者：
Anton, A
Puertolas, T
Ramos, M
Barnadas, A
Florian, J
Grande, R
Ribelles, N
Lomas, M
机构：
[1] Hosp Miguel Servet, Zaragoza, Spain
[2] Ctr Oncol, Coruna, Spain
[3] Hosp Germans Trias & Pujol, Badalona, Spain
[4] Hosp Barbastro, Huesca, Spain
[5] Hosp Virgen Victoria, Malaga, Spain
[6] Hosp Infanta Cristina, Badajoz, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
751
引用
收藏
页码：64S / 64S
页数：1
相关论文
共 50 条
  • [1] Phase II study with the combination of capecitabine (C) and vinorelbine (V) in metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes.
    Estevez, LG
    Batista, N
    Sánchez-Rovira, P
    Velasco, A
    Domine, M
    Lobo, F
    Oramas, J
    Cruz, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 63S - 63S
  • [2] Phase II clinical trial of ixabepilone in metastatic breast cancer (MBC) patients previously untreated with taxanes.
    Denduluri, N.
    Lee, J. J.
    Walshe, J. M.
    Yang, S. X.
    Vatas, U.
    Chow, C. K.
    Steinberg, S. M.
    Cox, M. C.
    Low, J. A.
    Swain, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 40S - 40S
  • [3] Phase II study of gemcitabine and capecitabine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
    Ahn, JH
    Kim, SB
    Lee, JS
    Kang, YK
    Kim, WK
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 101S - 101S
  • [4] Gemcitabine in metastatic breast cancer patients previously treated with anthracyclines and taxanes. Evaluation of response toxicity
    Lerzo, GL
    Temperley, G
    Rosales, C
    Campos, C
    Lezcano, A
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S74 - S74
  • [5] Phase II study of capecitabine (Xeloda®) in pts with advanced breast cancer (ABC), previously treated with anthracyclines and taxanes.
    Fumoleau, P
    Largillier, R
    Trillet-Lenoir, V
    Orfeuvre, H
    Extra, JM
    Lesimple, T
    Culine, S
    Montestruc, F
    Mouri, Z
    Gauducheau, CHR
    BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 285 - 285
  • [6] Safety and efficacy of low-dose metronomic cyclophosphamide plus vinorelbine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes.
    Kudo, Shun
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] UFT plus Oral Folinic Acid with Alternating Oral and Intravenous Vinorelbine in Patients with Metastatic Breast Cancer Previously Treated with Anthracyclines and Taxanes
    Coskun, Ugur
    Kaya, Ali Osman
    Alkis, Necati
    Buyukberber, Sueleyman
    Alici, Sueleyman
    Celenkoglu, Goekhan
    Uncu, Dogan
    Ozkan, Metin
    Sevinc, Alper
    Benekli, Mustafa
    ONKOLOGIE, 2009, 32 (10): : 562 - 566
  • [8] A multicentric phase II study with vinorelbine and protracted fluorouracil infusion for advanced breast cancer patients previously treated with anthracyclines and/or taxanes. Is salvage chemotherapy for metastatic breast cancer always effective and well tolerated?
    Kanaev, S
    Novikov, S
    Jukova, L
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S70 - S70
  • [9] Biweekly vinorelbine and tegafur/uracil in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: GEICAM 2000–02 phase II study
    Antonio Antón
    Agustí Barnadas
    Jesús Florián
    Nuria Ribelles
    María Lomas
    Juan Lao
    Ana González-Quintás
    Mireia Margelí
    Ana Belén Paules
    Javier Gayo
    Manuel Ramos
    Clinical and Translational Oncology, 2011, 13
  • [10] Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes
    Jones, Alison
    O'Brien, Mary
    Sommer, Harald
    Nowara, Elzbieta
    Welt, Anja
    Pienkowski, Tadeusz
    Rolski, Janusz
    Pham, My-Linh
    Perraud, Kevin
    Trillet-Lenoir, Veronique
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (04) : 755 - 763
12345